Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.31 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.31 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
| ▸ | CSF1R | P07333 | 1/20 | 0.30 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1266902 | 0.96 | HTR7 (0.32) | HTR7CHRM3MKNK1MAP2K1MAPK14 | |
| SCHEMBL1265873 | 0.93 | HCRTR1 (0.35) | CHRM3MKNK1HCRTR2ALDH1A1HCRTR1 | |
| SCHEMBL3833958 | 0.89 | P2RX3 (0.32) | — | |
| SCHEMBL1266634 | 0.88 | HTR7 (0.33) | HTR7HCRTR2ALDH1A1HCRTR1 | |
| SCHEMBL1265809 | 0.87 | MAPK14 (0.33) | HTR7CHRM3MKNK1MAPK14HCRTR2 | |
| SCHEMBL1266187 | 0.87 | RAB9A (0.37) | CSF1RHCRTR2HCRTR1 | |
| SCHEMBL1265114 | 0.87 | MAPT (0.34) | MKNK1HCRTR2ALDH1A1HPGDHCRTR1 | |
| SCHEMBL1267229 | 0.84 | FFAR1 (0.32) | — | |
| SCHEMBL1266782 | 0.83 | MAPT (0.38) | HCRTR2ALDH1A1HPGDHCRTR1 | |
| SCHEMBL1266969 | 0.82 | HRH3 (0.34) | HTR7HCRTR2HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034495-A1 | Method of Modulating Stress-Activated Protein Kinase System | INTERMUNE, INC. (US) | 2011-02-10 | — | — | US | disclosed |
| US-7521460-B2 | Thienopyridone derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2009-04-21 | — | — | US | disclosed |
| US-20070099894-A1 | e.g. 3-[(2,4-Difluorophenyl)amino]-2-{[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]carbonyl}-7-phenylthieno[2,3-b]pyridin-6(7H)-one; autoimmune, neurodegenerative disorders, antiinflammatory agent; p38 MAP kinase inhibitor | CELLTECH R&D LIMITED (GB) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034495-A1 | Method of Modulating Stress-Activated Protein Kinase System | MAPKAPK2, MAP3K6, MAP3K2 | HTR7 1515/4885CHRM3 2882/4885MKNK1 35/4885 |
| US-20070099894-A1 | e.g. 3-[(2,4-Difluorophenyl)amino]-2-{[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]carbonyl}-7-phenylthieno[2,3-b]pyridin-6(7H)-one; autoimmune, neurodegenerative disorders, antiinflammatory agent; p38 MAP kinase inhibitor | MAPK1, MAPKAPK2, MAPK6 | HTR7 781/4885CHRM3 3675/4885MKNK1 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.